Trial Profile
Low-dose decitabine combined with modified busulfan/ cyclophosphamide as a conditioning regimen followed by allogeneic stem cell transplantation for the treatment of high-risk patients with acute myeloid leukaemia: a prospective randomized controlled clinical study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2016
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 26 Apr 2016 New trial record